Our Plans and Their Implementation

Strategy for Clinical Translation and Development

Since 2012, we have been systematically developing a novel, clinically applicable cancer immunotherapy based on the synergy between innate and adaptive immunity. This method, known as MBTA therapy, induces rapid necrosis of tumor tissue, followed by a long-lasting T cell response targeting tumor neoantigens. In preclinical models across seven cancer types, we have repeatedly achieved the complete eradication of advanced tumors.

As of 2023, the project has received institutional support from BioCanim, a.s., a company established specifically for the development and clinical implementation of MBTA therapy.

Goals for 2025–2027

• Establish GMP-compliant production of all MBTA components
• Complete toxicological testing in GLP-certified laboratories
• Initiate a Phase I clinical trial

These steps are essential for progressing to Clinical trials II and III and subsequently to registration of new drug.

Estimated Budget

CZK 40–50 million (approximately EUR 1.6–2 million)

Implementation Strategy

The first clinical trial will take place in the Czech Republic with the support of experienced oncologists and immunologists. Once validated, we intend to expand our international collaborations.

Funding Options

To support this effort, we are establishing a nonprofit foundation with fully transparent financial oversight. All donations, grants, and private sponsorships will be dedicated exclusively to clinical testing and GMP production. Our ultimate goal is to make MBTA therapy available to patients as quickly as possible and at minimal cost.